Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
| ▸ | CCR5 | P51681 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.43 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840135 | 0.87 | PTGER1 (0.49) | PTGDR2LRRK2PTGER1RXRARXRB | |
| SCHEMBL5367447 | 0.79 | PTGDR2 (0.60) | PTGDR2CCR5LMNAUSP2LRRK2 | |
| SCHEMBL6530691 | 0.75 | PTGDR2 (0.56) | PTGDR2CCR5LMNAUSP2LRRK2 | |
| SCHEMBL5778498 | 0.75 | CCR5 (0.55) | PTGDR2CCR5LMNAUSP2LRRK2 | |
| SCHEMBL7076425 | 0.74 | KMT2A (0.46) | CCR5LMNAUSP28USP25ALDH1A1 | |
| SCHEMBL30955958 | 0.74 | PTGER1 (0.54) | CCR5LMNALRRK2PTGER1RXRA | |
| SCHEMBL3726426 | 0.74 | PTGER1 (0.54) | CCR5LMNALRRK2PTGER1RXRA | |
| SCHEMBL384896 | 0.72 | FOLH1 (0.68) | PTGDR2LMNALRRK2PTGER1ALDH1A1 | |
| SCHEMBL6452235 | 0.71 | PTGDR2 (0.67) | PTGDR2LMNAUSP2LRRK2ALDH1A1 | |
| SCHEMBL2537002 | 0.71 | USP28 (0.60) | PTGDR2CCR5LMNAPTGER1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124903-A1 | SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2011-05-26 | — | — | US | disclosed |
| US-20100217034-A1 | Process for the Preparation of Fesoterodine | ACTAVIS GROUP PTC EHF (IS) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100217034-A1 | Process for the Preparation of Fesoterodine | ADRB3, FES, QDPR | PTGDR2 2082/4885CCR5 3033/4885LMNA 4369/4885 |
| US-20110124903-A1 | SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES | FES, NISCH, RPS27A | PTGDR2 1748/4885CCR5 4613/4885LMNA 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.